Nuclear export is essential for the tumor‐promoting activity of survivin

Survivin appears to function as an apoptosis inhibitor and a regulator of cell division during development and tumorigenesis. Here we report the molecular characterization of the nucleocytoplasmic transport of survivin and its potential implications for tumorigenesis. We identified an evolutionary conserved Crm1‐dependent nuclear export signal (NES) in survivin. In dividing cells, the NES is essential for tethering survivin and the survivin/Aurora‐B kinase complex to the mitotic machinery, which in turn appears to be essential for proper cell division. In addition, export seems to be required for the cytoprotective activity of survivin, as export‐deficient survivin fails to protect tumor cells against chemo‐and radiotherapy‐induced apoptosis. These findings appear to be clinically relevant since preferential nuclear localization of survivin correlated with enhanced survival in colorectal cancer patients. Targeting survivin's nuclear export by the application of NES‐specific antibodies promoted its nuclear accumulation and inhibited its cytoprotective function. We demonstrate that nuclear export is essential for the biological activity of survivin and promote the identification of molecular decoys to specifically interfere with survivin's nuclear export as potential anticancer therapeutics. Knauer, S. K., Krämer, O. H., Knösel, T., Engels, K., Rödel, F., Kovács, A. F., Dietmaier, W., Klein‐Hitpass, L., Habtemichael, N., Schweitzer, A., Brieger, J., Rödel, C., Mann, W., Petersen, I., Heinzel, T., Stauber, R. H. Nuclear export is essential for the tumor‐promoting activity of survivin. FASEB J. 21, 207–216 (2007)

[1]  W. Wels,et al.  Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition , 2006, Cell Death and Differentiation.

[2]  R. Stauber,et al.  Acetylation of Stat1 modulates NF-B activity , 2006 .

[3]  C. Schoch,et al.  Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia , 2005, Cancer.

[4]  E. Ferrando-May.  Nucleocytoplasmic transport in apoptosis , 2005, Cell Death and Differentiation.

[5]  Grischa Toedt,et al.  Patient-based cross-platform comparison of oligonucleotide microarray expression profiles , 2005, Laboratory Investigation.

[6]  R. Pepperkok,et al.  Translocation Biosensors to Study Signal‐Specific Nucleo‐Cytoplasmic Transport, Protease Activity and Protein–Protein Interactions , 2005, Traffic.

[7]  C. Rödel,et al.  Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. , 2005, Cancer research.

[8]  T. Karpova,et al.  Crm1 is a mitotic effector of Ran-GTP in somatic cells , 2005, Nature Cell Biology.

[9]  B. Vincenzi,et al.  Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients , 2005, British Journal of Cancer.

[10]  D. Tan,et al.  Nuclear or cytoplasmic expression of survivin: What is the significance? , 2005, International journal of cancer.

[11]  D. Hallahan,et al.  Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma , 2005, Cancer.

[12]  Shirley K. Knauer,et al.  Nuclear Export Is Evolutionarily Conserved in CVC Paired-Like Homeobox Proteins and Influences Protein Stability, Transcriptional Activation, and Extracellular Secretion , 2005, Molecular and Cellular Biology.

[13]  E. Martinelli,et al.  Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters , 2005, British Journal of Cancer.

[14]  Chaohong Sun,et al.  Solution structure of human survivin and its binding interface with Smac/Diablo. , 2005, Biochemistry.

[15]  D. Altieri,et al.  Mitochondrial Dynamics Of Survivin And “Four Dimensional” Control Of Tumor Cell Apoptosis , 2005, Cell cycle.

[16]  F. Li,et al.  Role of survivin and its splice variants in tumorigenesis , 2004, British Journal of Cancer.

[17]  G. Giaccone,et al.  Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Salmon,et al.  The dynamic kinetochore-microtubule interface , 2004, Journal of Cell Science.

[19]  A. Chakravarti,et al.  Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms , 2004, Oncogene.

[20]  W. Earnshaw,et al.  Chromosomal passengers: the four-dimensional regulation of mitotic events , 2004, Chromosoma.

[21]  H. Stein,et al.  Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. , 2004, Neuroendocrinology.

[22]  John Calvin Reed,et al.  An IAP-IAP Complex Inhibits Apoptosis* , 2004, Journal of Biological Chemistry.

[23]  Tak W. Mak,et al.  Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.

[24]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[25]  J. Massagué,et al.  Nucleocytoplasmic shuttling of signal transducers , 2004, Nature Reviews Molecular Cell Biology.

[26]  W. Earnshaw,et al.  Aurora-B Phosphorylation in Vitro Identifies a Residue of Survivin That Is Essential for Its Localization and Binding to Inner Centromere Protein (INCENP) in Vivo* , 2004, Journal of Biological Chemistry.

[27]  Pamela A. Silver,et al.  Nuclear transport and cancer: from mechanism to intervention , 2004, Nature Reviews Cancer.

[28]  I. Petersen,et al.  Overexpression of Cyclooxygenase-2 Correlates With Chromosomal Gain at the Cyclooxygenase-2 Locus and Decreased Patient Survival in Advanced Colorectal Carcinomas , 2004, Diseases of the colon and rectum.

[29]  W. Sessa,et al.  Regulation of survivin function by Hsp90 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Clevers,et al.  Survivin and molecular pathogenesis of colorectal cancer , 2003, The Lancet.

[31]  M. Mesri,et al.  Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  L. O’Driscoll,et al.  Prognostic importance of survivin in breast cancer , 2003, British Journal of Cancer.

[33]  Karsten Weis,et al.  Regulating Access to the Genome Nucleocytoplasmic Transport throughout the Cell Cycle , 2003, Cell.

[34]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[35]  G. Giaccone,et al.  CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. , 2002, Experimental cell research.

[36]  R. Stauber,et al.  Qualitative Highly Divergent Nuclear Export Signals Can Regulate Export by the Competition for Transport Cofactors in Vivo , 2001, Traffic.

[37]  P. Vigneri,et al.  Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.

[38]  H. J. Kim,et al.  An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. , 2001, Biochemistry.

[39]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Gulnik,et al.  Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells. , 1998, Virology.

[41]  R. Stauber,et al.  Acetylation of Stat1 modulates NF-kappaB activity. , 2006, Genes & development.

[42]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.